NMD Pharma A/S: Financial statements 2019
CVR: 36899069
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
NMD Pharma A/S (CVR 36899069) has filed annual accounts for 2019. In 2019, the company reported a gross profit of EUR -7,132,039 and a net result of EUR -8,501,273 compared with EUR -5,542,829 the year before. Equity in the 2019 report amounted to EUR 140,238. The company had 17 employees in the financial year.
- Gross Profit
- EUR -7,132,039
- Profit/Loss
- EUR -8,501,273
- Equity
- EUR 140,238
- Employees
- 17
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | -7.1 mio. EUR | -8.5 mio. EUR | 140 t. EUR | 17 |
| 2018 | - | -4.7 mio. EUR | -5.5 mio. EUR | 88 t. EUR | 14 |
| 2017 | - | -17.9 mio. | -21.9 mio. | -8.7 mio. | 13 |
| 2016 | - | -6.4 mio. | -6.9 mio. | 13.1 mio. | 5 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of August 10, 2019, Paul Brian Little has left the board of directors of NMD Pharma A/S.
NMD Pharma A/S has published its annual report for 2018. Gross profit came to DKK -4,661,848, and the net result was DKK -5,542,829.
As of May 23, 2019, Jeremy Paul Springhorn has joined the board of directors of NMD Pharma A/S.
As of May 23, 2019, Fiona MacLaughlin has joined the board of directors of NMD Pharma A/S.
As of May 23, 2019, Lucas Antoine de Breed has left the board of directors of NMD Pharma A/S.
About NMD Pharma A/S
NMD Pharma A/S is a Danish company of the type Aktieselskab based in Aarhus N, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named NMD Pharma ApS. The management consists of Thomas Holm Pedersen. The board consists of Michael Thomas Heffernan (chair), Anja Ulrike Harmeier, Christian Ellebæk Elling and Ivan Andreevich Burkov. The company's owners include LUNDBECKFOND INVEST A/S, Novo Holdings A/S and Roche Finance Ltd.. The company has 64 employees (2026). In 2025, the company reported a gross profit of EUR -26,063,175 and a net result of EUR -32,985,370 compared with EUR -32,253,700 the year before. Equity in the 2025 report amounted to EUR 12,410,475.